| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Walsh Colin serves as a Director at ATTO. Across recent SEC filings that breaks down to 4 buys and 46 sells. Those positions are worth an estimated $51.4M at current prices.
The biggest single holding is ATTO (~$51.4M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 958,386 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. Common Stock | Director | Buy | 585,000 | $17.58 | $10,285,000.00 | +24.0% | |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. Common Stock | Director | Buy | 585,000 | $17.58 | $10,285,000.00 | +24.0% | |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. Common Stock | Director | Sell | 105,807 | $21.28 | $2,251,657.70 | -100% | |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. Common Stock | Director | Sell | 105,807 | $21.28 | $2,251,657.70 | -100% |